Dedicated Medical Device Law: Draft Bill Still Pending Since 2018

1. Key takeaways

The legislative status of Myanmar’s dedicated medical device law is as follows: the draft law has been submitted to the Attorney General Office; after approval, it must be submitted again to the Myanmar Parliament for comment. This means that until the domestic legislative conversion is complete, Myanmar will continue to operate through administrative guidelines backed by the catch-all authorisation of the Public Health Law (1972).

GRZAN note: when planning over the medium to long term, companies must treat the possible enactment of the dedicated law within the planning horizon as a preset variable. Once that variable materialises, documentary requirements, review procedures and entity eligibility may all adjust with it. The practical implication is not merely to watch for the change but to build submissions today in a form that can absorb the change, so that adaptation means reformatting rather than rebuilding, and so that a rule change never catches the company with a dossier architecture that contradicts it.

2. Legal basis

The table below summarises the official source of the status, the current stage of the draft law, Myanmar’s regional commitments and the instruments that govern in the meantime. Together the rows describe a system that is internationally aligned but domestically unfinished, which is the defining feature of the Myanmar regulatory environment.

3. Expert insights

Insight 1: the legislative process divides into an Attorney General Office approval stage and a parliamentary deliberation stage. The former is a legal-technical review; the latter is a political procedure. The dedicated law does not take effect until both are complete. For planning purposes this two-stage structure matters because each stage has its own dynamics and its own duration, and neither is within the company’s influence; the only rational response is to keep the tracking continuous and the assumptions flexible.

Insight 2: the 5-year harmonisation period counted from 2016 has passed without the dedicated law taking effect. This time lag tells companies that Myanmar’s legislative progress should not be forecast on a conventional timetable. A schedule assumption that would be reasonable elsewhere is not reasonable here, and plans that hard-code a near-term enactment date will repeatedly need revision; plans that treat enactment as a variable to be tracked will not. The lesson generalises: in transitional markets, build the plan around the process rather than around the promised date.

Insight 3: the system has operated for more than two decades in the absence of a dedicated law. Since 2000, implemented through import notifications and import recommendations, the authority has accumulated stable review practice. Stability is the compensating virtue of this arrangement: although the legal hierarchy is unusual, the operative expectations are consistent, and a company that studies the actual review practice can predict the handling of a submission with reasonable confidence. Longevity of an administrative system is itself information, and here it signals that the absence of a statute has not meant the absence of standards.

Insight 4: once the dedicated law is enacted, the current administrative guidelines may be replaced in a systematised way. Companies should structure their dossiers according to the complete requirements of the AMDD so that they can adapt quickly. A dossier assembled to the full AMDD architecture is not wasted effort under the present system; it is precisely the shape that will map most directly onto whatever statutory framework eventually replaces the guidelines.

Insight 5: compared with ASEAN markets that have completed legislative conversion, Myanmar is in a transitional state. Compliance strategy should retain flexibility and avoid betting long-cycle investment on the current rules remaining unchanged. This does not argue for postponing market entry; it argues for entering with structures, contracts and documentation designed so that a change of rules changes the paperwork, not the strategy.

4. Practical recommendations

• Treat the enactment of the dedicated law as a preset planning variable. Reserve room in the dossier architecture for upgrading, so that new requirements can be layered onto the existing structure.
• Build the dossier structure to the complete requirements of the AMDD. This allows quick adaptation once the dedicated law is enacted and supports reuse across other ASEAN markets in the meantime.
• Insert a legislative-change clause into the authorised representative agreement. Agree in advance on how supplementary materials will be provided and how the associated costs will be borne.
• Track the progress of both the Attorney General Office and the parliamentary stages. Maintain a tracking ledger for legislative developments, updated on a fixed routine rather than by chance, since neither stage announces its completion in advance to the companies affected.
• Avoid betting long-term investment on the current rules remaining unchanged. Keep the strategy elastic, so that a change in the legal basis triggers a revision of documents rather than a revision of market plans.

5. Verification checklist

• □ The draft dedicated law has been confirmed as pending at the Attorney General Office
• □ It has been confirmed that the draft must be submitted again to Parliament for comment after approval
• □ Myanmar’s submission of the AMDD instrument of ratification in July 2018 has been recorded
• □ The dossier structure has been built to the complete requirements of the AMDD
• □ A legislative-change clause has been inserted into the authorised representative agreement
• □ A tracking ledger for legislative progress has been established
• □ Flexibility of the compliance strategy has been maintained

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com